A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

MLA

Turner, Nicholas C., et al. “A Plain Language Summary of the CAPItello-291 Study: Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.” Future Oncology, vol. 20, no. 37, Dec. 2024, pp. 2901–13. EBSCOhost, https://doi.org/10.1080/14796694.2024.2390791.

APA

Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortés, J., Gomez, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., Murillo, S. M., Park, Y. H., Sohn, J.-H., Toi, M., Tokunaga, E., Yousef, S., Zhukova, L., de Bruin, E., Grinsted, L., & Schiavon, G. (2024). A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer. Future Oncology, 20(37), 2901–2913. https://doi.org/10.1080/14796694.2024.2390791

Chicago

Turner, Nicholas C, Mafalda Oliveira, Sacha J Howell, Florence Dalenc, Javier Cortés, Henry L Gomez, Xichun Hu, et al. 2024. “A Plain Language Summary of the CAPItello-291 Study: Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.” Future Oncology 20 (37): 2901–13. doi:10.1080/14796694.2024.2390791.